Can pathogenic neuronal-surface antibodies alter receptor signaling or synaptic function?

Neuronal-surface autoantibodies are biologically capable of changing neural signaling, but the clinically meaningful effect depends on pathogenic activity and access to the relevant extracellular target within the nervous system. Experimental findings support this principle across defined antibody specificities.

Clinical and functional evidence

• Patient-derived glycine-receptor (GlyR) IgG rapidly reduced glycinergic synaptic currents in cultured motor neurons. Activity of Fab fragments indicates that direct receptor antagonism can occur without requiring antibody cross-linking alone.
• In vivo, transfer of patient antibodies reduced spinal GlyR clustering and impaired escape behavior in zebrafish, linking altered receptor organization to a measurable functional phenotype.
• CSF-derived CASPR2 monoclonal antibodies produced electrophysiologic, imaging, synaptic, and behavioral abnormalities after intrathecal transfer in rodents, directly demonstrating effects when antibodies reach the CNS compartment.

Mechanistic explanations

• GlyR antibodies can impair inhibitory neurotransmission through direct antagonism, receptor internalization, and reduced receptor-cluster abundance.
• CASPR2 antibodies bind the CASPR2 discoidin domain and disrupt CASPR2–contactin-2 binding. Because CASPR2 helps organize juxtaparanodal voltage-gated Kv1 channels, this interference can alter Kv1-channel localization or function and thereby neuronal excitability.
• D1 receptor-reactive IgG and monoclonal antibodies can activate D1R G-protein and β-arrestin signaling, showing that some neuronal antibodies may act as receptor agonists rather than blockers or internalizers.

Interpretation for clinical use

• Detection in serum alone does not establish CNS target exposure, pathogenicity, or causality. CSF evidence, syndrome concordance, and antibody-specific functional data materially strengthen interpretation.
• Mechanisms are antibody-specific: receptor antagonism, internalization, altered synaptic clustering, and disruption of ion-channel-associated protein interactions should not be assumed interchangeably.

Bottom line

• The claim is strongly supported: pathogenic neuronal-surface or ion-channel-associated antibodies can alter receptor signaling and synaptic function when they access their targets, with GlyR and CASPR2 providing particularly direct experimental examples.